LOGIN  |  REGISTER
Astria Therapeutics
Cue Biopharma

Aziyo Biologics to Present at the Cowen 43rd Annual Health Care Conference

February 27, 2023 | Last Trade: US$0.62 0.02 3.35

SILVER SPRING, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place on Monday, March 6, 2023, at 9:50 am ET.

A live webcast of the presentation can be accessed by visiting https://investors.aziyo.com/events-presentations or by clicking here. A replay will be available on the Company’s website following the event.

About Aziyo Biologics

Aziyo develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Aziyo’s mission is to humanize medical devices to improve patient outcomes. For more information, visit www.Aziyo.com.

Investors:
Matt Steinberg
FINN Partners
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
Courtney Guyer
Aziyo Biologics, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page